



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1206-B)

In the Application of:

Alex Burgin, et al

Application No.: 09/993,245

Filing Date: November 14, 2001

For: Structures and Methods for Designing
Topoisomerase I Inhibitors

Examiner: TBA

Group Art Unit: 1623

Confirmation No. 7743

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

RECEIVED

DEC 03 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

1. We are transmitting herewith the attached:

- a) Second Supplemental Information Disclosure Statement
- b) U.S. PTO 1449 form with copies of 8 references
- c) Return Receipt Postcard

2. With respect to additional fees:

No Additional Fee is Required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents and Trademarks, Washington, D.C. 20231 on this 22 day of November, 2002.

Dated: 11/22/02

By: [Signature]

Emily Miao
Reg. No. 35,285

McDONNELL BOEHNEN HULBERT & BERGHOFF
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001; Fax (312) 913-0002



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1206-B)

In the Application of:

Alex Burgin, et al

Application No.: 09-993,245

Filing Date: November 14, 2001

For: Structures and Methods for Designing
Topoisomerase I Inhibitors

Commissioner for Patents and Trademarks
Washington, D.C. 20231

)
) Examiner: TBA
)
) Group Art Unit: 1623
)
) Confirmation No. 7743
)
)
)

RECEIVED

DEC 03 2002

TECH CENTER 1600/2900

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. Brünger, A. T., et al., "Crystallography and NMR system: A new software system for macromolecular structure determination," *Acta Crystallographica*, D54, pp. 905-921 (1998)
2. Champoux, J. J., "Structure-based analysis of the effects of camptothecin on activities of human topoisomerase I," *Ann. N. Y. Acad. Sci.*, Volume 922, pp. 56-64 (2000).

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

3. McRee, D.E., "XtalView/Xfit- A Versatile Program for Manipulating Atomic Coordinates and Electron Density," *J. Struct. Bio.*, Volume 125, p. 156-165 (1999)
4. Navaza, J., "AMORE: an automated package for molecular replacement," *Acta. Crystallogr.*, A50, pp. 157-163 (1994).
5. Otwinoski, Z., et al., "Processing of X-ray diffraction data in oscillation mode," *Methods. Enzymol.*, Volume 276, pp. 307-326 (1997).
6. Rodgers, D. W., "Cryocrystallography," *Structure*, Volume 2, pp. 1135-1140 (1994).
7. Sheldrick, G., et al., "SHELXL: High-resolution Refinement," *Methods in Enzymology*, Volume 277, pp. 319-343 (1997).
8. Wall, M. E., et al., "The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata*," *J. Am. Chem. Soc.*, Volume 88, pp. 3888-3890 (1966)

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the

Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.


Early and favorable consideration is earnestly solicited.

Dated: _____

11/22/02


McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone : (312) 913-0001
Facsimile: (312) 913-0002

Respectfully submitted,



Emily Miao
Registration No. 35,285

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
00-1206-BSerial No.
09/993,245
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
RECEIVED

Applicant: Alex Burgin, et al.

DEC 03 2002

Filing Date: 11/14/01

Group: 1623

TECH CENTER 1600/2900
U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

1.	Brünger, A. T., et al., "Crystallography and NMR system: A new software system for macromolecular structure determination," <i>Acta. Crystallographica</i> , D54, pp. 905-921 (1998)
2.	Champoux, J. J., "Structure-based analysis of the effects of camptothecin on activities of human topoisomerase I," <i>Ann. N. Y. Acad. Sci.</i> , Volume 922, pp. 56-64 (2000).
3.	McRee, D.E., "XtalView/Xfit: A Versatile Program for Manipulating Atomic Coordinates and Electron Density," <i>J. Struct. Bio.</i> , Volume 125, p. 156-165 (1999)
4.	Navaza, J., "AMORE: an automated package for molecular replacement," <i>Acta. Crystallogr.</i> , A50, pp. 157-163 (1994).
5.	Otwinoski, Z., et al., "Processing of X-ray diffraction data in oscillation mode," <i>Methods. Enzymol.</i> , Volume 276, pp. 307-326 (1997).
6.	Rodgers, D. W., "Cryocrystallography," <i>Structure</i> , Volume 2, pp. 1135-1140 (1994).
7.	Sheldrick, G., et al., "SHELXL: High-resolution Refinement," <i>Methods in Enzymology</i> , Volume 277, pp. 319-343 (1997).
8.	Wall, M. E., et al., "The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from <i>Camptotheca acuminata</i> ," <i>J. Am. Chem. Soc.</i> , Volume 88, pp. 3888-3890 (1966)

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.